At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.
|Articles|July 1, 1995
Oncology NEWS International
- Oncology NEWS International Vol 4 No 7
- Volume 4
- Issue 7
DaunoXome Is Recommended for Approval for Kaposi's Sarcoma
BOULDER, Colo--NeXstar Pharmaceuticals, Inc. has announced that the FDA's Oncologic Drugs Advisory Committee (ODAC) has recommended approval of DaunoXome, NeXstar's liposomal formulation of daunorubicin, as first-line therapy for Kaposi's sarcoma. ODAC made its recommendation upon review of the company's amended NDA, which included data from NeXstar's phase III study of 227 HIV-positive patients with advanced Kaposi's sarcoma.
Advertisement
BOULDER, Colo--NeXstar Pharmaceuticals, Inc. has announced thatthe FDA's Oncologic Drugs Advisory Committee (ODAC) has recommendedapproval of DaunoXome, NeXstar's liposomal formulation of daunorubicin,as first-line therapy for Kaposi's sarcoma. ODAC made its recommendationupon review of the company's amended NDA, which included datafrom NeXstar's phase III study of 227 HIV-positive patients withadvanced Kaposi's sarcoma.
Articles in this issue
over 31 years ago
House Panel Holds Hearing on Self-Referralover 31 years ago
Health-Related Legislationover 31 years ago
Mitoguazone Appears Promising in HIV-Associated Refractory NHLover 31 years ago
Responses to Anti-HER2 MoAb Seenover 31 years ago
MoAb May Improve Detection of Colon And Rectal Cancerover 31 years ago
Zeneca Files NDA for ArimidexAdvertisement
Related to this article
Ayal Aizer, MD, MHS, discussed Alliance A071801 data favoring fractionated SRS over single-fraction SRS after brain metastasis resection.
Marcio A. Fagundes, MD, explained how proton therapy and rectal spacers can reduce radiation exposure to the rectum, bowel, and bladder in prostate cancer.
Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.
Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
Community physicians must be “smart” when it comes to initiating outpatient care with agents like ramantamig for multiple myeloma, according to Jeffrey V. Matous, MD.
In the phase 3 Alliance A071801 trial, postoperative fractionated SRS improved surgical bed control vs single-fraction SRS without added toxicity.
Advertisement
Advertisement
Trending on CancerNetwork
1
EXCALIBER-RRMM: Iberdomide in Relapsed/Refractory Multiple Myeloma
2
Alliance A071801 Supports Fractionated SRS After Brain Metastasis Surgery
3
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
4
FDA OKs Pirtobrutinib in Frontline CLL/SLL
5